TY - JOUR
AR - AJMC-2022-1-101
TI - Non-Small Cell Lung Cancer; Review of Mutations and Tyrosine Kinase Inhibitors
AU - Dhara , Dave
AU - Basheer , Mohammed
AU - Janakikeerthika, Dharmarpandi
AU - Darshit , Dave
AU - Rohit , Saralaya
AU - Praveen , Tumula
JO - American Journal of Medicinal Chemistry
PY - 2022
DA - Fri 01, Jul 2022
SN - 2733-2519
DO - http://dx.doi.org/10.31487/j.AJMC.2022.01.01
UR - https://www.sciencerepository.org/non-small-cell-lung-cance_AJMC-2022-1-101 
KW - Non-small cell lung cancer (NSCLC), tyrosine kinase inhibitors (TKIs), germline mutations, ALK mutation, CHEK2 mutation
AB - Lung cancer is the leading cause of cancer-related death in the United States and the incidence of this in never smokers is about 15-20% in males and about 50% in females. Non-small cell lung carcinoma (NSCLC) constitutes about 75% to 80% of these cancers and is more common than small cell lung carcinoma (SCLC) in never smokers. Treatment of NSCLC has been rapidly evolving with the discovery of targetable mutations like EGFR, and ALK. Despite this, prognosis of NSCLC remains guarded given diagnosis at an advanced stage as well as patient factors like age and comorbidities. The standard of care should include therapy customized to suit the patient. In this review article we report the first known case of checkpoint mutation seen in a patient with NSCLC and summarize the common mutations along with targeted therapy with tyrosine kinase inhibitors.